Summary:

In this article, the authors evaluate the efficacy and safety of a long acting bronchodilator combination known as umeclindinium/vilanterol. The study was a randomized double-blind placebo-controlled study which included a total of 1178 patients older than 40 years old, were current/former smokers with COPD. The patients were randomized into three different groups and one placebo group; UMEC 62.5 mcg, UMEC/VI 62.5/25 mcg; VI 25 mcg. The patients enrolled had COPD that was characterized by airflow limitation that was not fully reversible. The primary outcome that was measured was the forced expiratory volume in one second on day 169. Other measures that were assessed were the lung function, symptoms, and health related quality of life endpoints, rescue salbutamol use, and shortness of breath with daily activity index. The results showed a statistically significant improvement in the FEV₁ compared to the placebo. There were increases with umeclidinium/vilanterol than with just monotherapy alone. In conclusion, once daily umeclidinium/vilanterol was well tolerated and provided statistically significant improvement in both lung function and symptoms in COPD patients.

This entry is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license.